A new genetic prediction model successfully identified individuals with elevated lipoprotein(a) [Lp(a)] levels across diverse populations with 81% positive predictive value, requiring only 1.2 genetic tests to find one true case of elevation above 125 nmol/L. The haplotype-based approach explained 46% of Lp(a) variation and performed consistently across different ancestries in over 50,000 participants from multiple biobanks. This represents a critical advancement in cardiovascular risk assessment, as elevated Lp(a) affects roughly 20% of the global population and significantly increases atherosclerotic disease risk, yet fewer than 1% of Americans currently receive clinical Lp(a) testing. The genetic approach could leverage existing genomic data from biobanks and direct-to-consumer testing to identify high-risk individuals without additional blood draws. However, this preprint awaits peer review, and results may change. The model's 14.4-fold improvement over current clinical detection rates could transform preventive cardiology by enabling opportunistic screening in genotyped populations, though implementation would require integration with electronic health records and validated clinical protocols for managing identified high-risk individuals.